Please login to the form below

Not currently logged in
Email:
Password:

Positive results for Herceptin alternative

Research by the US National Cancer Institute has suggested investigational breast cancer treatment affitoxin is effective in targeting HER2-positive tumours that have stopped responding to Herceptin

Research by the US National Cancer Institute has suggested investigational breast cancer treatment affitoxin is effective in targeting HER2-positive tumours that have stopped responding to current treatment Herceptin (trastuzumab).

The study, which involved using the protein on mice, was developed to research alternative therapies for cancers over expressing the HER2 gene, with current therapies ineffective for many tumours.

Results showed that affitoxin is a 'potent agent' that is able to destroy HER2 over expressing cells at low concentrations and was well-tolerated by mice.

In his conclusion, author of the study, Dr Jacek Capala, National Cancer Institute, said: "Our findings showed that HER2-affitoxin is an effective anticancer agent and a potential candidate for clinical studies."

Delyth Morgan, chief executive of Breast Cancer Campaign, pressed the need for an alternative to Herceptin: "Historically, women with HER2-positive breast cancer had few treatments available to them. Herceptin changed that and is arguably one of the biggest advances in breast cancer in the last 20 years."

He continued: "However, in many cases Herceptin eventually stops working for these women. If affitoxin realises its potential as a new treatment for HER2-positive breast cancer, it may overcome this issue of resistance and become an important alternative treatment."

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics